← Back to jobs

Manager, Financial Reporting and Accounting

Company
Immix Biopharma, Inc.
Location
Remote - United States
Work type
Full Time
Posted
2026-10-05

Job description

Manager of Financial Reporting & Accounting, responsible for reviewing monthly and quarterly close document, SEC filings, equity administration, regulatory financial reporting, and external audit relationship. Reporting directly to the VP of Finance & Accounting. Reviews and prepares financial documents as assigned. The role is perfect for a Big 4 senior or manager who wants real ownership, direct exposure to the CFO-level agenda, the Audit Committee cycle, and a company moving from clinical-stage toward commercialization.

Description
Key responsibilities
Monthly and quarterly close

• Lead review of the monthly and quarterly close: journal entries, account reconciliations, accruals and flux analysis, working with our outsourced and internal preparers.

• Own the close calendar and checklist; drive it to a timeline that supports 10-Q and 10-K deadlines.

• Review R&D accounting, including clinical trial accruals and prepaid balances for CROs, CDMOs and investigator sites, with input from clinical operations.

• Prepare or review technical accounting memos for new agreements and non-routine transactions (financings, warrants, license and collaboration agreements, leases).

SEC reporting

• Prepare and review Forms 10-Q and 10-K, including financial statements, footnotes, MD&A and XBRL tagging review.

• Support Forms 8-K, proxy statement compensation and equity tables, Section 16 support, and registration statements (S-3, S-8, ATM and offering-related filings, comfort letter support).

• Maintain the disclosure checklist, tie-out binders and support packages; coordinate with outside counsel, the financial printer and the Disclosure Committee.

• Monitor new SEC rules and FASB standards and assess their impact on the company.

Equity administration oversight and reporting

• Oversee the equity plan administrator and the equity ledger: grants, exercises, cancellations, share reserve and plan limits.

• Own stock-based compensation accounting under ASC 718: valuation inputs, expense schedules, modifications, and footnote disclosure.

• Prepare EPS and dilution calculations, warrant and option roll-forwards, and equity reporting for the Board and Compensation Committee.

Regulatory financial reporting

• Prepare or coordinate non-SEC financial filings: Nasdaq compliance items, government surveys, state and local filings, and foreign subsidiary statutory reporting as applicable.

• Coordinate with external tax advisors on the income tax provision (ASC 740), R&D credits and related filings.

• Support financial data required for grant, federal healthcare or transparency reporting as the company approaches commercialization.

External audit and internal controls

• Serve as the day-to-day contact for the external auditors on quarterly reviews and the annual audit: PBC lists, timelines, open-item tracking and issue resolution.

• Maintain and improve SOX internal controls over financial reporting: risk assessment, control documentation, key report and IPE support, and remediation of any findings.

• Help prepare Audit Committee materials each quarter.

Building for what is next

• Help design the accounting policies, processes and controls needed for commercial launch: inventory and cost of goods, revenue recognition (ASC 606), gross-to-net, and system improvements.

• Identify and implement process automation in a small-team environment.

Qualifications
Required

• Bachelor's degree in accounting or a related field; active CPA (or all exam sections passed).

• 5 to 8+ years of progressive experience, including Big 4 audit experience at the senior or manager level serving SEC registrants.

• Hands-on experience preparing or auditing Forms 10-Q and 10-K, with strong working knowledge of U.S. GAAP, SEC reporting rules (Regulation S-X and S-K) and SOX 404.

• Working knowledge of stock-based compensation (ASC 718), equity and warrant accounting, and EPS.

• Proven ability to work independently on a small team: you review at a manager level and are equally willing to build the schedule yourself.

• Clear writing. You can draft a footnote, an accounting memo and an Audit Committee slide without heavy editing.

• Strong Excel skills and comfort with a cloud ERP, an equity administration platform and SEC filing/XBRL software.

Preferred

• Experience with public life sciences companies, ideally covering both R&D-stage and commercial-stage pharma or biotech, as an auditor or in industry.

• Familiarity with clinical trial accruals, CRO and CDMO contracts, and license or collaboration agreements.

• Exposure to commercial-launch accounting: inventory, ASC 606 revenue and gross-to-net.

• Experience with capital markets transactions (ATM programs, follow-on offerings, shelf registrations, comfort letters).

• Experience at a smaller reporting company or emerging growth company where one person covers a lot of ground.

• One to three years in industry after public accounting is a plus, not a requirement.

Why this role
• Ownership. You are the second senior finance professional at a Nasdaq-listed company, not one reviewer among many. Your work goes to the CFO-level agenda, the Audit Committee and the SEC.

• Breadth. Close, SEC reporting, equity, audit and controls in one seat. Few roles at larger companies offer that range before the Director level.

• Support. You work directly with the VP of Finance & Accounting, who stays close to the technical work and is invested in your development.

• Timing. You join ahead of a potential commercial transition and help build the finance function that supports it.

• Path. Clear room to grow into Senior Manager, Director of SEC Reporting or Controller as the company scales.

In your first 12 months you will have led review of four quarter-end closes, filed three 10-Qs and a 10-K on time, run a clean annual audit and SOX cycle as the auditors' day-to-day contact, and taken over equity administration oversight and stock compensation reporting.

Original source